U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07469189) titled 'A Study on Hydroxocobalamin Given to Healthy Individual to Monitor Symptoms' on March 10.
Brief Summary: We are planning a series of studies in individuals with ulcerative colitis, primary sclerosing cholangitis and pouchitis to determine if hydroxocobalamin is an effective therapy to treat these conditions. For these indications we are submitting INDs to the FDA as well as protocols to the IRB. Hydroxocobalamin, referred to as vitamin B12a has been approved by the FDA for treatment of cyanide toxicity in up to 5 grams intravenously over 15 minutes twice in a brief period. This has been tested and used in intravenous doses as high ...